CoChat

EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance

Open access
Abbas, Noura, Mourad, Mohamad, Smaily, Hiba, Al Mahmasani, Layal, Shamseddine, Ali · 2026 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with nearly one quarter of patients presenting with metastatic disease at diagnosis. The epidermal growth factor receptor (EGFR) plays a central role in CRC pathogenesis through activation of downstream RAS/RAF/MAPK and PI3K/AKT/mTOR signaling pathways, and has become a major therapeutic target. Anti-EGFR monoclonal antibodies, cetuximab and panitumumab, have demonstrated survival benefit in selected patients, particularly those with left-sided, RAS wild-type tumors. However, primary and acquired resistance limit their efficacy, underscoring the need for predictive biomarkers and novel strategies. This review synthesizes current knowledge of EGFR biology, therapeutic integration, and biomarker development, including RAS and BRAF mutations, MSI status, HER2 amplification, EGFR ligands (AREG/EREG), consensus molecular subtypes, and liquid biopsy applications. We also discuss mechanisms of resistance such as pathway reactivation, receptor mutations, and epithelial-to-mesenchymal transition, alongside emerging approaches, including combination regimens, ctDNA-guided rechallenge, and genotype-specific inhibitors. Collectively, these insights highlight the evolving landscape of precision oncology in CRC and the importance of molecular stratification to optimize EGFR-targeted therapy and overcome resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms27073265

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 EGFR signaling pathways in CRC under normal and oncogenic conditions. AKT, Protein Kinase B; AREG, Amphiregulin; EGF, Epidermal Growth Factor; EGFR, Epidermal Growth Factor Receptor (HER1/ErbB1); ERK, Extracellular Signal-Regulated Kinase (MAPK); EREG, Epiregulin; GDP, Guanosine Diphosphate; GTP, Guanosine Triphosphate; GRB2, Growth factor Receptor-Bound Protein 2; JAK/STAT, Janus Kinase/Signal Transducer and Activator of Transcription; MEK, Mitogen-Activated Protein Kinase Kinase (MAP2K); mTOR, Mechanistic Target of Rapamycin; PI3K, Phosphoinositide 3-Kinase; PIP3, Phosphatidylinositol 3,4,5-trisphosphate; PLCγ, Phospholipase C-gamma; PTEN, Phosphatase and Tensin Homolog; RAF, Rapidly Accelerated Fibrosarcoma (serine/threonine kinase); RAS, Rat Sarcoma (small GTPase); SOS, Son of Sevenless (guanine nucleotide exchange factor); TGF-α, Transforming Growth Factor-alpha.
Figure 1 EGFR signaling pathways in CRC under normal and oncogenic conditions. AKT, Protein Kinase B; AREG, Amphiregulin; EGF, Epidermal Growth Factor; EGFR, Epidermal Growth Factor Receptor (HER1/ErbB1); ERK, Extracellular Signal-Regulated Kinase (MAPK); EREG, Epiregulin; GDP, Guanosine Diphosphate; GTP, Guanosine Triphosphate; GRB2, Growth factor Receptor-Bound Protein 2; JAK/STAT, Janus Kinase/Signal Transducer and Activator of Transcription; MEK, Mitogen-Activated Protein Kinase Kinase (MAP2K); mTOR, Mechanistic Target of Rapamycin; PI3K, Phosphoinositide 3-Kinase; PIP3, Phosphatidylinositol 3,4,5-trisphosphate; PLCγ, Phospholipase C-gamma; PTEN, Phosphatase and Tensin Homolog; RAF, Rapidly Accelerated Fibrosarcoma (serine/threonine kinase); RAS, Rat Sarcoma (small GTPase); SOS, Son of Sevenless (guanine nucleotide exchange factor); TGF-α, Transforming Growth Factor-alpha.CC BY · PubMed Central
Figure 2 EGFR signaling in mCRC: Biomarkers, mechanisms of resistance, and novel strategies. ADC, Antibody Drug Conjugate; Amp, Amplification; AREG, Amphiregulin; BRAF, v-RAF Murine Sarcoma Viral Oncogene Homolog B1; CMS2, Consensus Molecular Subtype 2; ctDNA, Circulating Tumor DNA; dMMR, Deficient Mismatch Repair; DHA, Dehydroascorbic Acid (oxidized Vitamin C); EGFR, Epidermal Growth Factor Receptor (HER1/ErbB1); EREG, Epiregulin; Extracellular Signal-Regulated Kinase (MAPK); GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; GLUT1, Glucose Transporter 1; HER2, Human Epidermal Growth Factor Receptor 2; MET, Hepatocyte Growth Factor Receptor; MEK, Mitogen-Activated Protein Kinase Kinase (MAP2K); mCRC, Metastatic Colorectal Cancer; MSI-H, Microsatellite Instability-High; MSS, Microsatellite Stable; Mut, Mutation; PI3K, Phosphoinositide 3-Kinase; RAF, Rapidly Accelerated Fibrosarcoma (serine/threonine kinase); RAS, Rat Sarcoma (small GTPase); ROS, Reactive Oxygen Species; T-DXd, Trastuzumab Deruxtecan (HER2-targeted antibody-drug conjugate); WT, Wild Type.
Figure 2 EGFR signaling in mCRC: Biomarkers, mechanisms of resistance, and novel strategies. ADC, Antibody Drug Conjugate; Amp, Amplification; AREG, Amphiregulin; BRAF, v-RAF Murine Sarcoma Viral Oncogene Homolog B1; CMS2, Consensus Molecular Subtype 2; ctDNA, Circulating Tumor DNA; dMMR, Deficient Mismatch Repair; DHA, Dehydroascorbic Acid (oxidized Vitamin C); EGFR, Epidermal Growth Factor Receptor (HER1/ErbB1); EREG, Epiregulin; Extracellular Signal-Regulated Kinase (MAPK); GAPDH, Glyceraldehyde-3-Phosphate Dehydrogenase; GLUT1, Glucose Transporter 1; HER2, Human Epidermal Growth Factor Receptor 2; MET, Hepatocyte Growth Factor Receptor; MEK, Mitogen-Activated Protein Kinase Kinase (MAP2K); mCRC, Metastatic Colorectal Cancer; MSI-H, Microsatellite Instability-High; MSS, Microsatellite Stable; Mut, Mutation; PI3K, Phosphoinositide 3-Kinase; RAF, Rapidly Accelerated Fibrosarcoma (serine/threonine kinase); RAS, Rat Sarcoma (small GTPase); ROS, Reactive Oxygen Species; T-DXd, Trastuzumab Deruxtecan (HER2-targeted antibody-drug conjugate); WT, Wild Type.CC BY · PubMed Central
Figure 3 EGFR signaling in mCRC: Anatomical and molecular subtypes, biomarkers, and treatment strategies. AKT, Protein Kinase B; Amp, Amplification; AREG, Amphiregulin; BRAF, v-RAF Murine Sarcoma Viral Oncogene Homolog B1; CMS, Consensus Molecular Subtype; dMMR, Deficient Mismatch Repair; ECD, Extracellular Domain; EGF, Epidermal Growth Factor; EGFR, Epidermal Growth Factor Receptor (HER1/ErbB1); ERK, Extracellular Signal-Regulated Kinase (MAPK); EREG, Epiregulin; GDP, Guanosine Diphosphate; GRB2, Growth factor Receptor-Bound Protein 2; GTP, Guanosine Triphosphate; HER2, Human Epidermal Growth Factor Receptor 2; JAK/STAT, Janus Kinase/Signal Transducer and Activator of Transcription; MET, Hepatocyte Growth Factor Receptor; MEK, Mitogen-Activated Protein Kinase Kinase (MAP2K); mTOR, Mechanistic Target of Rapamycin; MSI-H, Microsatellite Instability-High; MSS, Microsatellite Stable; Mut, Mutation; NTRK, Neurotrophic Tyrosine Receptor Kinase; ORR, Objective Response Rate; P, Phosphorylation; PI3K, Phosphoinositide 3-Kinase; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-Kinase Catalytic Subunit Alpha; PIP3, Phosphatidylinositol 3,4,5-trisphosphate; PLCγ, Phospholipase C-gamma; PTEN, Phosphatase and Tensin Homolog; RAF, Rapidly Accelerated Fibrosarcoma (serine/threonine kinase); RAS, Rat Sarcoma (small GTPase); RET, Rearranged during Transfection proto-oncogene; ROS1, c-ros Oncogene 1; SOS, Son of Sevenless (guanine nucleotide exchange factor); T-DXd, Trastuzumab Deruxtecan; TGF-α, Transforming Growth Factor-alpha; VEGF, Vascular Endothelial Growth Factor; WT, Wild Type.
Figure 3 EGFR signaling in mCRC: Anatomical and molecular subtypes, biomarkers, and treatment strategies. AKT, Protein Kinase B; Amp, Amplification; AREG, Amphiregulin; BRAF, v-RAF Murine Sarcoma Viral Oncogene Homolog B1; CMS, Consensus Molecular Subtype; dMMR, Deficient Mismatch Repair; ECD, Extracellular Domain; EGF, Epidermal Growth Factor; EGFR, Epidermal Growth Factor Receptor (HER1/ErbB1); ERK, Extracellular Signal-Regulated Kinase (MAPK); EREG, Epiregulin; GDP, Guanosine Diphosphate; GRB2, Growth factor Receptor-Bound Protein 2; GTP, Guanosine Triphosphate; HER2, Human Epidermal Growth Factor Receptor 2; JAK/STAT, Janus Kinase/Signal Transducer and Activator of Transcription; MET, Hepatocyte Growth Factor Receptor; MEK, Mitogen-Activated Protein Kinase Kinase (MAP2K); mTOR, Mechanistic Target of Rapamycin; MSI-H, Microsatellite Instability-High; MSS, Microsatellite Stable; Mut, Mutation; NTRK, Neurotrophic Tyrosine Receptor Kinase; ORR, Objective Response Rate; P, Phosphorylation; PI3K, Phosphoinositide 3-Kinase; PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-Kinase Catalytic Subunit Alpha; PIP3, Phosphatidylinositol 3,4,5-trisphosphate; PLCγ, Phospholipase C-gamma; PTEN, Phosphatase and Tensin Homolog; RAF, Rapidly Accelerated Fibrosarcoma (serine/threonine kinase); RAS, Rat Sarcoma (small GTPase); RET, Rearranged during Transfection proto-oncogene; ROS1, c-ros Oncogene 1; SOS, Son of Sevenless (guanine nucleotide exchange factor); T-DXd, Trastuzumab Deruxtecan; TGF-α, Transforming Growth Factor-alpha; VEGF, Vascular Endothelial Growth Factor; WT, Wild Type.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 5

Metadata

Authors
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A.
Affiliations
  • American University of Beirut Medical Center (LB)
  • Department of Internal Medicine, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Riad El Solh, Beirut 1107-2020, Lebanon
Corresponding author
Shamseddine, Ali
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-04-03
Volume
27
Issue
7
Pages
3265
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7149929304
Cited by
4
References
135
Citations by year
2026: 4
FWCI
3.71
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
colorectal cancer, EGFR signaling, anti-EGFR monoclonal antibody, cetuximab, panitumumab, treatment resistance, predictive biomarkers, RAS mutations, BRAF mutation, microsatellite instability, HER2 amplification, EGFR ligands, consensus molecular subtypes, liquid biopsy, combination therapy, precision oncology, RAS/MAPK pathway, PI3K/AKT/mTOR pathway, epithelial-mesenchymal transition, molecular stratification
MeSH terms
Antineoplastic Agents, Immunological, Humans, Mutation, Biomarkers, Tumor, Colorectal Neoplasms, Signal Transduction, Drug Resistance, Neoplasm, Epithelial-Mesenchymal Transition, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.